Want to see PHVS full AI Analyst Report?
Pharvaris (PHVS) AI Stock Analysis
Top Page
Pharvaris
(NASDAQ:PHVS)
Overall score is held back primarily by weak financial performance (no revenue, widening losses, and heavy cash burn), partially offset by a strong low-debt balance sheet. Technical conditions are currently favorable with the price in an uptrend and positive momentum, but valuation remains challenging due to negative earnings and no dividend.
Pharvaris (PHVS) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $2.34B
- Dividend Yield
- ―
- Average Volume (3M)
- 801.31K
- Price to Earnings (P/E)
- -11.1
- Beta (1Y)
- 0.38
- Revenue Growth
- ―
- EPS Growth
- 9.42%
- Country
- US
- Employees
- 148
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Pharvaris Business Overview & Revenue Model
Company Description
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a...
Pharvaris Financial Statement Overview
Summary
Financials are mixed for a development-stage biotech: the balance sheet is strong with extremely low debt and sizable equity, but the company remains pre-revenue with widening net losses and substantial ongoing cash burn (TTM operating/free cash flow around -$156M).
Income Statement
14Very NegativeBalance Sheet
63PositiveCash Flow
22Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -106.45K | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -172.17M | -173.29M | -145.42M | -99.57M | -86.56M | -42.31M |
| Net Income | -171.57M | -175.70M | -134.22M | -100.88M | -76.33M | -42.73M |
Balance Sheet | ||||||
| Total Assets | 328.67M | 301.45M | 291.37M | 398.69M | 167.73M | 212.09M |
| Cash, Cash Equivalents and Short-Term Investments | 318.28M | 291.68M | 280.73M | 391.23M | 161.84M | 209.35M |
| Total Debt | 673.73K | 776.80K | 861.47K | 238.91K | 436.82K | 250.18K |
| Total Liabilities | 27.86M | 30.18M | 23.61M | 14.65M | 18.47M | 7.14M |
| Stockholders Equity | 300.81M | 271.27M | 267.76M | 384.05M | 149.26M | 204.95M |
Cash Flow | ||||||
| Free Cash Flow | -156.09M | -137.24M | -120.67M | -93.14M | -67.29M | -44.73M |
| Operating Cash Flow | -155.99M | -137.07M | -120.13M | -93.05M | -67.16M | -44.60M |
| Investing Cash Flow | -100.11K | -164.62K | -538.09K | -89.98K | -124.30K | -130.03K |
| Financing Cash Flow | 266.52M | 160.61M | 2.68M | 325.39M | 8.65M | 143.67M |
Pharvaris Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PHVS, the sentiment is Positive. The current price of 33.53 is above the 20-day moving average (MA) of 31.03, below the 50-day MA of 33.66, and above the 200-day MA of 31.00, indicating a neutral trend. The MACD of -0.10 indicates Negative momentum. The RSI at 59.57 is Neutral, neither overbought nor oversold. The STOCH value of 96.22 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PHVS.
Pharvaris Risk Analysis
Pharvaris disclosed 82 risk factors in its most recent earnings report. Pharvaris reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
2 New RisksPharvaris Peers Comparison
Overall Rating
PHAR65Neutral- PHVS58Neutral
BCRX57Neutral
OMER48Neutral
KRSA47Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| PHAR | 65Neutral | $864.10M | 34.56 | 8.96% | ― | 6.67% | 2242.07% |
| PHVS | 58Neutral | $2.34B | -11.10 | -61.24% | ― | ― | 9.42% |
| BCRX | 57Neutral | $2.16B | -5.89 | 101.55% | ― | 68.72% | -737.08% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| OMER | 48Neutral | $1.33B | 9.65 | -109.40% | ― | ― | ― |
| KRSA | 47Neutral | $1.37B | -2.50 | -87.96% | ― | -12.60% | -126.24% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PHVS | Pharvaris N.V. | 33.53 | 11.03 | 49.02% | |
| BCRX | BioCryst Pharmaceuticals | 8.47 | 1.61 | 23.47% | |
| OMER | Omeros Corporation | 18.44 | 11.27 | 157.18% | |
| KRSA | Korsana Biosciences, Inc. | 30.14 | 17.12 | 131.49% | |
| PHAR | Pharming Group Nv | 12.23 | -1.09 | -8.18% | |
| ADRX | ADARx Pharmaceuticals, Inc. | 17.00 | -2.35 | -12.14% |
Pharvaris Corporate Events
Pharvaris Unveils CHAPTER-3 Phase 3 Topline Data and HAE Pipeline Milestones
Pharvaris N.V., based in Leiden, the Netherlands, is a clinical‑stage biopharmaceutical company focused on hereditary angioedema (HAE). Its lead investigational products, deucrictibant immediate‑release capsules for on‑demand treatm...
Pharvaris Posts Strong Phase 3 HAE Prophylaxis Data for Oral Deucrictibant XR
On September 8, 2026, Pharvaris reported positive topline results from its CHAPTER-3 pivotal Phase 3 study of once-daily deucrictibant XR for prophylaxis of hereditary angioedema attacks. The global, double-blind trial in 85 adolescents and adults ac...
Pharvaris Posts Q2 2026 Results as Deucrictibant Nears Key Phase 3 Data and Regulatory Milestones
On August 12, 2026, Pharvaris reported second-quarter 2026 results and highlighted continued clinical and regulatory momentum for deucrictibant, including an FDA review of the immediate-release capsule for on-demand hereditary angioedema treatment an...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 09, 2026